

Donald E Cutlip

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6024689/publications.pdf>

Version: 2024-02-01

101
papers

18,617
citations

71061

41
h-index

39638

94
g-index

101
all docs

101
docs citations

101
times ranked

13591
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical End Points in Coronary Stent Trials. <i>Circulation</i> , 2007, 115, 2344-2351.	1.6	4,993
2	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. <i>Circulation</i> , 2011, 123, 2736-2747.	1.6	3,378
3	Updated Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1438-1454.	1.2	1,560
4	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. <i>European Heart Journal</i> , 2012, 33, 2403-2418.	1.0	900
5	Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2010, 362, 1663-1674.	13.9	812
6	Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1735.	3.8	759
7	Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. <i>Circulation</i> , 2018, 137, 2635-2650.	1.6	435
8	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 240-261.	1.6	428
9	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Circulation</i> , 2018, 137, 961-972.	1.6	368
10	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019, 40, 2632-2653.	1.0	335
11	Beyond Restenosis. <i>Circulation</i> , 2004, 110, 1226-1230.	1.6	283
12	Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents. <i>Circulation</i> , 2009, 119, 680-686.	1.6	282
13	Evaluation and Treatment of Patients With Lower Extremity Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 931-941.	1.2	269
14	Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2211-2221.	1.2	240
15	Supervised Exercise, Stent Revascularization, or Medical Therapy for Claudication Due to Aortoiliac Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 999-1009.	1.2	225
16	Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. <i>Lancet, The</i> , 2017, 390, 1843-1852.	6.3	214
17	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1021-1034.	1.2	211
18	Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles. <i>Journal of the American College of Cardiology</i> , 2015, 66, 278-307.	1.2	191

#	ARTICLE	IF	CITATIONS
19	Standardized End Point Definitions for Coronary Intervention Trials. <i>European Heart Journal</i> , 2018, 39, 2192-2207.	1.0	179
20	In-Hospital and 1-Year Outcomes Among Percutaneous Coronary Intervention Patients With Chronic Kidney Disease in the Era of Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 37-45.	1.1	139
21	Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. <i>Circulation</i> , 2021, 143, 479-500.	1.6	132
22	Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	6.3	112
23	Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2017, 69, 679-691.	1.2	110
24	A Randomized Trial of a Dedicated Bifurcation Stent Versus Provisional Stenting in the Treatment of Coronary Bifurcation Lesions. <i>Journal of the American College of Cardiology</i> , 2015, 65, 533-543.	1.2	101
25	Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2213-2223.	1.2	99
26	Troponin Criteria for Myocardial Infarction After Percutaneous Coronary Intervention. <i>Archives of Internal Medicine</i> , 2012, 172, 502.	4.3	98
27	Impact of Smoking on Clinical and Angiographic Restenosis After Percutaneous Coronary Intervention. <i>Circulation</i> , 2001, 104, 773-778.	1.6	87
28	Antiplatelet Therapy Duration Following Bare Metal or Drug-Eluting Coronary Stents. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1113.	3.8	82
29	Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. <i>American Journal of Cardiology</i> , 2003, 92, 977-980.	0.7	78
30	DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2492-2502.	1.2	78
31	Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3287-3297.	1.2	73
32	Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1343-1353.	1.1	68
33	Is fibromuscular dysplasia underdiagnosed? A comparison of the prevalence of FMD seen in CORAL trial participants versus a single institution population of renal donor candidates. <i>Vascular Medicine</i> , 2014, 19, 363-367.	0.8	61
34	Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure. <i>Circulation</i> , 2022, 145, 1592-1604.	1.6	54
35	Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1552-1562.	1.1	51
36	Relationship of Albuminuria and Renal Artery Stent Outcomes. <i>Hypertension</i> , 2016, 68, 1145-1152.	1.3	50

#	ARTICLE	IF	CITATIONS
37	Carotid angiographic characteristics in the CREST trial were major contributors to periprocedural stroke and death differences between carotid artery stenting and carotid endarterectomy. <i>Journal of Vascular Surgery</i> , 2016, 63, 851-858.e1.	0.6	50
38	Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 138-147.	1.1	49
39	Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. <i>Circulation</i> , 2016, 133, 1772-1782.	1.6	47
40	Corticosteroid therapy in refractory shock following cardiac arrest: a randomized, double-blind, placebo-controlled, trial. <i>Critical Care</i> , 2016, 20, 82.	2.5	46
41	Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1954-1962.	1.1	44
42	Thrombotic Complications Associated With Early and Late Nonadherence to Dual Antiplatelet Therapy. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 404-410.	1.1	41
43	Autopsy Validation Study of the Academic Research Consortium Stent Thrombosis Definition. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 554-559.	1.1	40
44	Periprocedural Myocardial Infarction in a Randomized Trial of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 150-156.	1.4	40
45	Renal Artery Stent Outcomes. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2487-2494.	1.2	40
46	Causes of late mortality with dual antiplatelet therapy after coronary stents. <i>European Heart Journal</i> , 2015, 37, ehv614.	1.0	38
47	Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials. <i>European Heart Journal</i> , 2018, 39, 1687-1697.	1.0	38
48	Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles. <i>European Heart Journal</i> , 2015, 36, 1851-1877.	1.0	37
49	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1468-1483.	1.2	35
50	The Academic Research Consortium Governance Charter. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 595-596.	1.1	33
51	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. <i>Circulation</i> , 2022, 145, 847-863.	1.6	28
52	Cost Effectiveness of Supervised Exercise, Stenting, and Optimal Medical Care for Claudication: Results From the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) Trial. <i>Journal of the American Heart Association</i> , 2014, 3, e001233.	1.6	27
53	Effects of Stenting for Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1180-1188.	2.2	25
54	Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 805-819.	1.1	24

#	ARTICLE	IF	CITATIONS
55	Extracranial Carotid Disease Revascularization. <i>Circulation</i> , 2012, 126, 2636-2644.	1.6	23
56	Type 4a myocardial infarction: Incidence, risk factors, and long-term outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 849-856.	0.7	23
57	Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007331.	1.4	23
58	Dedicated Bifurcation Stent for the Treatment of Bifurcation Lesions Involving Large Side Branches. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1338-1346.	1.1	22
59	Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting. <i>JAMA Cardiology</i> , 2017, 2, 478.	3.0	22
60	Outcomes of a dedicated stent in coronary bifurcations with large side branches: A subanalysis of the randomized <sc>TRYTON</sc> bifurcation study. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 1231-1241.	0.7	20
61	Roll-in Experience from the Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) Study. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 511-520.	0.2	19
62	Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. <i>Circulation</i> , 2016, 134, 989-998.	1.6	19
63	Periprocedural Stroke and Myocardial Infarction as Risks for Long-Term Mortality in CREST. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004663.	0.9	18
64	Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). <i>Circulation</i> , 2017, 135, 1720-1732.	1.6	17
65	Defining Staged Procedures for Percutaneous Coronary Intervention Trials. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 823-832.	1.1	17
66	Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium. <i>American Heart Journal</i> , 2017, 190, 76-85.	1.2	16
67	Impact of Time from Symptom Onset to Drug Administration on Outcome in Patients Undergoing Glycoprotein IIb/IIIa Facilitated Primary Angioplasty (from the EGYPT Cooperation). <i>American Journal of Cardiology</i> , 2015, 115, 711-715.	0.7	15
68	Accreditation and funding for a 24-month advanced interventional cardiology fellowship program: A call to action for optimal training of the next generation of interventionalists. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 1010-1015.	0.7	15
69	Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcomes. <i>Circulation</i> , 2005, 112, 916-22; discussion 922.	1.6	14
70	Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach. <i>American Heart Journal</i> , 2017, 193, 35-45.	1.2	13
71	Factors associated with performing urgent coronary angiography in out-of-hospital cardiac arrest patients. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 832-839.	0.7	13
72	APPOSITION V: STENTYS coronary stent system clinical trial in subjects with ST-segment elevation myocardial infarction—Rationale and design. <i>American Heart Journal</i> , 2014, 168, 652-660.e2.	1.2	11

#	ARTICLE	IF	CITATIONS
73	Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005308.	1.4	9
74	Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 675-681.	1.0	9
75	Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE). <i>Cardiovascular Revascularization Medicine</i> , 2022, 34, 17-24.	0.3	9
76	<p>Prediction of cardiovascular outcomes with machine learning techniques: application to the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) study</p>. <i>International Journal of Nephrology and Renovascular Disease</i> , 2019, Volume 12, 49-58.	0.8	5
77	Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. <i>EuroIntervention</i> , 2023, 19, e807-e831.	1.4	5
78	Usefulness of Postmarket Studies to Evaluate Long-Term Safety of Coronary Eluting Stents (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50)	0.7	4
79	Regional and physician specialty" associated variations in the medical management of atherosclerotic renal" artery stenosis. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 443-452.	2.3	4
80	Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50)	0.7	4
81	Safety and Effectiveness of the SVELTE Fixed-Wire and Rapid Exchange Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions: Results of the OPTIMIZE Randomized Study. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010609.	1.4	4
82	Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb", "-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. <i>American Heart Journal</i> , 2022, 245, 19-28.	1.2	4
83	Device and Procedure Relatedness. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 783-788.	1.1	4
84	Mortality After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007008.	1.4	3
85	Drug-eluting stent era: will we improve 5-year outcomes?. <i>Coronary Artery Disease</i> , 2006, 17, 289-292.	0.3	2
86	Drug-eluting stent era: will we improve 5-year outcomes?. <i>Coronary Artery Disease</i> , 2006, 17, 681-684.	0.3	2
87	Current issues in coronary artery stenting in the elderly. <i>Aging Health</i> , 2007, 3, 105-114.	0.3	2
88	Risk Assessment to Predict Arterial and Venous Events in Patients Undergoing Percutaneous Coronary Intervention. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 478-483.	0.7	2
89	Trust and transparency in clinical trials of medical devices. <i>Nature Reviews Cardiology</i> , 2015, 12, 503-504.	6.1	2
90	Five year clinical outcomes of the COBRA Polyzyene F NanoCoated Coronary Stent System. <i>Cardiovascular Revascularization Medicine</i> , 2022, , .	0.3	2

#	ARTICLE	IF	CITATIONS
91	Frequency of the Use of Low- Versus High-Dose Aspirin in Dual Antiplatelet Therapy After Percutaneous Coronary Intervention (from the Dual Antiplatelet Therapy Study). American Journal of Cardiology, 2014, 113, 1146-1152.	0.7	1
92	A 54-Year-Old Woman With a Single Coronary Artery and Watershed Ischemia Treated With Nitrates. JACC: Cardiovascular Interventions, 2015, 8, e91-e94.	1.1	1
93	Validation of Standardization. Circulation: Cardiovascular Interventions, 2019, 12, e008569.	1.4	1
94	Anatomic and Flow Characteristics of Left Anterior Descending Coronary Artery Angiographic Stenoses Predisposing to Myocardial Infarction. American Journal of Cardiology, 2021, 141, 7-15.	0.7	1
95	SCAI Interventional Cardiology Board Review â€“ Second Edition Kern Morton J., ed. 472 pages. Philadelphia, PA: Lippincott Williams & Wilkins, 2014. \$154.99. Circulation, 2014, 129, .	1.6	0
96	Value-Based Hypothesis Testing for Cardiac Device Clinical Trials. Circulation: Cardiovascular Interventions, 2016, 9, e003627.	1.4	0
97	Diabetes, Kidney Disease, and Coronary Stents - A Complex Interaction. Cardiovascular Revascularization Medicine, 2019, 20, 1081-1082.	0.3	0
98	On the Bleeding Edge. Circulation: Cardiovascular Interventions, 2020, 13, e009128.	1.4	0
99	Editorial: A REMEDEE for Very Late Stent Failure?. Cardiovascular Revascularization Medicine, 2020, 21, 571-572.	0.3	0
100	Percutaneous Coronary Intervention in Patients with Diabetes and Multivessel or Left Main Diseaseâ€”A Review. US Cardiology Review, 2012, 9, 108-111.	0.5	0
101	ROSES â€“ Avoiding the Thorns. Cardiovascular Revascularization Medicine, 2022, 36, 71-72.	0.3	0